Guest Column | November 19, 2026

Outsourcing Manufacturing Doesn't Outsource Diversion Risk

By Stella-Maris Onwuama, UNC Kenan-Flagler Business School

Forecast-GettyImages-1769832504

When a sponsor sends a Schedule II drug or a product containing a List I chemical to a CDMO, the CDMO has the Drug Enforcement Administration (DEA) registration and holds the controlled substance records. If the material is lost, stolen, or cannot be accounted for, though, the customer, the regulator, and the public will still look at the sponsor's name and brand. The sponsor therefore needs to have a clear view of how its CDMO accounts for the controlled material (losses, waste, and destruction).

I learned that at the National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria, where I was a regulatory officer in the Narcotics and Controlled Substances Directorate during my national service year, auditing the pharmaceutical and narcotic warehouses and facilities throughout Delta State. That work taught me that records are useful only if they can be reconciled to what's actually in the warehouse. A complete paper trail in itself doesn't prove that the stock recorded is actually there.

Banks learned that lesson a long time ago. A vendor's own rules don't prove that its controls work, and they in no way absolve the bank of responsibility. In 2023, the federal banking regulators set out a life cycle approach to third-party risk: planning, due diligence and selection, contract negotiation, ongoing monitoring, and termination. The FDA takes a similar approach to quality: Regardless of what the manufacturer does, the owner remains responsible. A sponsor can bring the same level of rigor to diversion risk by embedding controls into the three phases of the CDMO relationship: selection, the agreement, and ongoing management.

Why Sponsors Still Own This Risk

Federal rules place the controlled substance obligations on the DEA registrant, not the sponsor. A CDMO that is manufacturing controlled substances must register, meet the security requirements, maintain records, and take a full inventory at least every two years. If there is a theft or a significant loss, it must notify its DEA Field Division in writing within one business day and file DEA Form 106 within 45 days. With respect to listed chemicals, a regulated person must report any unusual or excessive loss and file DEA Form 107 within 15 days.

Each of those obligations is owed by the CDMO to the DEA. None of them confers any right on the sponsor to receive prompt notice of a loss, to have access to reconciliations, or to be able to audit. The sponsor may only find out about a reportable loss after the regulator has, or may not find out at all. The sponsor is left with the supply disruption, the customer concern, and the reputational damage. That's a commercial exposure. That's not a transfer of the CDMO's DEA obligations, and that's only going to be resolved through contract and through oversight.

Due Diligence Responsibilities During CDMO Selection

A sponsor has the most leverage before signing. The 2023 interagency guidance treats due diligence as a separate phase and lists legal compliance, incident reporting, physical security, and subcontractor oversight among the factors to consider. A sponsor can, of course, ask the CDMO the same questions about diversion risk. 

Start with authorization and supply. Is each site that is going to be handling the product registered for that activity? For Schedule II work, who has the procurement or manufacturing quota, and will that quota support the volumes you intend to manufacture? DEA's online validation tool is only accessible to registrants, so the sponsor will be required to request the current registration certificates and supporting documentation from the CDMO and check those against DEA.

Next, ask for the compliance history: the DEA inspection findings and responses, any Orders to Show Cause, and any settlements or Memoranda of Agreement. Ask how many Form 106 and Form 107 loss reports the CDMO has filed over the past three to five years, what the reasons were, and what was corrected.

Then test the controls. How does the CDMO secure the Schedule II material? How does it screen its staff and remove their access when they leave?

Finally, ask how often the CDMO reconciles its records against physical stock and who actually does the count. In my audit work, that question separated sites that actually had controls and those that just had good paper.

What To Include In The Agreement

The 2023 interagency guidance provides a model of the typical terms that banks would negotiate: compliance obligations, incident notification, audit and remediation rights, subcontracting restrictions, and termination rights. 

The FDA recommends that the quality agreement focuses on the cGMP obligations and is kept distinct from the commercial terms. A controlled substance schedule in the supply agreement (with the appropriate cross-reference to the quality agreement for batch records and investigations) provides the link between the two while giving the diversion controls their own space.

cGMP requires the CDMO to calculate actual yield and percentage of theoretical yield at each relevant stage of manufacture. The schedule should require those figures to be provided to the sponsor with agreed variance thresholds, which would trigger an investigation and a written report.

The schedule should also require the CDMO to advise the sponsor as soon as it advises the DEA of a theft or loss of the sponsor's material and to provide copies of the Form 106 or Form 107. It should require copies of the destruction records (including Form 41 where required).

The sponsor should require prior written approval of the subcontractors with the same controls flowing down and should have routine and for-cause audit rights over the inventories and reconciliations. A corrective action plan should be triggered by repeated unexplained variances or an unreported loss, and termination rights should be available if the problems continue to recur.

Ongoing Management Responsibilities

A careful selection and a good contract only really matter if someone looks at what the CDMO reports. The 2023 interagency guidance defines monitoring as ongoing and risk-based, covering the review of performance and control reports, audit results, and any changes to key personnel or subcontractors. For a sponsor, a high-volume Schedule II program would warrant more frequent reconciliation reviews and audits.

DEA's theft and loss rule provides a ready-made framework for looking across reporting periods. In determining whether a loss is significant, a registrant weighs the amount and nature of the product, the probability of diversion, and whether the losses form a pattern over time. Sponsors can do the same. Look at the yield variances, the unexplained losses, the waste, and the destruction across batches and quarters so that small losses don't just get swallowed up in the individual reports.

The sponsor should appoint one owner for the CDMO relationship and have the quality, supply chain, and compliance teams all look at the data. The review should be rerun following a loss report, an inspection finding, a change of ownership or key personnel, a new subcontractor, or a site change. Variances should be escalated, the corrective actions should be tracked, and the next review should be used to confirm that the corrective action has in fact worked.

Closing The Gap

The 2026 National Drug Control Strategy is extremely clear in its view that the private sector is to play a role in securing the drug supply chain. There are significant costs attached to any business that "fails to secure its supply chain" (p. 24), and there is an explicit call for more pharmaceutical companies to participate in trusted trade programs such as the Customs-Trade Partnership Against Terrorism (CTPAT) (pp. 20, 23).

For the sponsor, the supply chain runs through the CDMO's vault. A complete paper trail doesn't prove that the stock recorded is actually in the vault. The sponsor can close that gap at three points: selection, the agreement, and ongoing management.

About The Author:

Stella-Maris Onwuama is a full-time MBA candidate at UNC Kenan-Flagler Business School (concentrating in corporate finance and business analytics). Previous roles include loan transaction and client operations at Citibank Europe and client service at BNY Mellon. She served as a regulatory officer in the Narcotics and Controlled Substances Directorate of Nigeria's NAFDAC (National Agency for Food and Drug Administration and Control) during her national service year and later worked in financial analytics at Sure-Life Pharmaceutical Industries.